American Journal of Respiratory Cell and Molecular Biology · 2023 · 22 citations · 26 references
Veterinary MedicineClinical SciencesInfectious DiseasesInflammationPulmonary Function TestingPulmonologyFibrosisInflammatory BiomarkersPulmonary Function AssessmentPulmonary InflammationPulmonary PathologyRespiratory DiseaseFibrosis QuantificationFibrotic ChangeHospital Stay DurationLung FibrosisLung Inflammation BiomarkersPneumonia Severity AssessmentPulmonary Fibrosis ProgressionPulmonary Function Changes
Abstract Beyond the acute infection of coronavirus disease (COVID-19), concern has arisen about long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of our study was to analyze if there is any biomarker of fibrogenesis in patients with COVID-19 pneumonia capable of predicting post-COVID-19 pulmonary sequelae. We conducted a multicenter, prospective, observational cohort study of patients admitted to a hospital with bilateral COVID-19 pneumonia. We classified patients into two groups according to severity, and blood sampling to measure matrix metalloproteinase 1 (MMP-1), MMP-7, periostin, and VEGF and respiratory function tests and high-resolution computed tomography were performed at 2 and 12 months after hospital discharge. A total of 135 patients were evaluated at 12 months. Their median age was 61 (interquartile range, 19) years, and 58.5% were men. We found between-group differences in age, radiological involvement, length of hospital stay, and inflammatory laboratory parameters. Differences were found between 2 and 12 months in all functional tests, including improvements in predicted forced vital capacity (98.0% vs. 103.9%; P = 0.001) and Dl CO <80% (60.9% vs. 39.7%; P = 0.001). At 12 months, 63% of patients had complete high-resolution computed tomography resolution, but fibrotic changes persisted in 29.4%. Biomarker analysis demonstrated differences at 2 months in periostin (0.8893 vs. 1.437 ng/ml; P < 0.001) and MMP-7 (8.7249 vs. 15.2181 ng/ml; P < 0.001). No differences were found at 12 months. In multivariable analysis, only 2-month periostin was associated with 12-month fibrotic changes (odds ratio, 1.0013; 95% confidence interval, 1.0006–1.00231; P = 0.003) and 12-month Dl CO impairment (odds ratio, 1.0006; 95% confidence interval, 1.0000–1.0013; P = 0.047). Our data suggest that early periostin postdischarge could predict the presence of fibrotic pulmonary changes.
26
Fleischner Society: Glossary of Terms for Thoracic Imaging
David M. Hansell, Alexander A. Bankier, Heber MacMahon et al. · Radiology · 2008 · 4.3K citations
Brian L. Graham, Irene Steenbruggen, Martin R. Miller et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 4.1K citations · Full text
Health Professions, Clinical Sciences, Internal Medicine +16
Jacob Cohen · Applied Psychological Measurement · 1983 · 1.5K citations · Full text